Observations that Syk and Btk are constitutively active in CLL cells [100–103] have prompted the development of new agents targeting the BCR signaling pathway, and inhibitors of Btk, Syk, and PI3Kδ have seen application in the therapy of CLL [4, 152–154]. This evidence concerns the gene SYK and B-cell chronic lymphocytic leukemia.